Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis

Jürgen H. Prochaska¹,²,³,⁴, Bernd Frank²,⁴, Markus Nagler²,⁴, Heidrun Lamparter²,⁴, Gerhard Weißer¹,⁴, Andreas Schulz⁵,⁶, Lisa Eggebretch⁶,⁷, Sebastian Göbel¹,³,⁴, Natalie Arnold⁴,⁵, Marina Panova-Noeva²,⁴, Iris Hermanns⁴,⁵, Antonio Pinto⁶,⁷, Stavros Konstantinides², Hugo ten Cate²,⁶, Karl J Lackner¹,²,⁷, Thomas Münzel¹,²,³,⁴, Christine Espinola-Klein¹,⁴ & Philipp S. Wild¹,³,⁴,⁵

Previous reports have investigated the impact of age on D-Dimer testing in elderly individuals with suspected deep vein thrombosis (DVT), but data on the age-related diagnostic value of D-dimer in a sample covering a broad age range are limited. The present study determined age-specifically the diagnostic accuracy of D-dimer and compared it to C-reactive protein (CRP), a marker of inflammation, in 500 patients with suspected DVT from the VTEval project (NCT02156401). Sensitivity of D-dimer was lower in patients < 60 years in comparison to patients ≥ 60 years (Δ−16.8%), whereas specificity was 27.9% higher. Lowest levels of sensitivity were detected for female sex, unprovoked DVT, low thrombotic burden, and distal DVT. A fixed D-dimer threshold of 0.25 mg/L FEU resulted in elevated sensitivity for patients < 60 with a reduction of false negatives by 40.0% for proximal DVT and by 50.0% for distal DVT. In patients < 60 years, D-dimer and CRP demonstrated comparable diagnostic performance for both proximal and distal DVT (p > 0.05). In conclusion, these data outline a clinically-relevant limitation of D-dimer testing among younger patients with suspected DVT indicating a necessity for age-adapted cut-off values. Further research is required to decrypt the role of inflammation in the pathophysiology and diagnosis of venous thrombosis.

Deep vein thrombosis (DVT) is a common disease with an age-dependently increasing incidence. It bears the risk for sequelae comprising pulmonary embolism as potentially life-threatening complication, post-thrombotic syndrome and recurrent venous thromboembolism¹. A combined assessment of the clinical probability of DVT and the measurement of the circulating D-dimer concentration are currently recommended as initial diagnostic approach for patients presenting with suspected proximal DVT, followed by compression duplex ultrasound (CDUS) as gold standard².

Although D-dimer is very specific for fibrin, the specificity for venous thromboembolism is poor³. Several clinical presentations have been demonstrated to come along with elevated concentrations of D-dimer (e.g. infection, malignancy, pregnancy)⁴. The finding that D-dimer concentrations increase with age implies practical
limitations of D-dimer testing in clinical routine. Therefore, age-dependent cut-off levels have been proposed for D-dimer testing in current guidelines for patients with suspected pulmonary embolism. In contrast, little attention has been drawn to the effect of age on the diagnostic performance of D-dimer in patients with suspected deep vein thrombosis, especially with regard to the distinct sub-entities proximal DVT and isolated distal DVT.

Against this background we aimed to assess the age-related diagnostic performance of D-dimer in patients presenting to a high-volume vascular centre for CDUS with suspected DVT. In order to display the strengths and weaknesses of D-dimer testing, we analysed its utility also with respect to distinct subtypes of DVT and compared its diagnostic performance to the inflammatory biomarker C-reactive protein (CRP).

Results
The analysis comprised data of 500 patients with suspected DVT, who were enrolled between April 2013 and June 2015. The characteristics of the study sample with a median age of 60.0 (IQR 45.0/72.0) years and slightly more females are presented in Table 1. The proportion of outpatients was 87.4% (n = 437) in the sample. In total, the cohort comprised 231 patients with confirmed DVT, whereas DVT was excluded in 269 patients. Among DVT cases, diagnoses of proximal DVT (48.1%) and isolated distal DVT (51.9%) were almost equally distributed. The correlation of the two D-dimer assays, which were used for D-dimer testing during the course of the study, was 0.973 (see Supplemental Table 1 and Supplemental Fig. 1). The STARD diagram describing the flow of participants through the study is displayed in Fig. 1.

D-dimer for the diagnosis of DVT. Age-specific levels of sensitivity and specificity of D-dimer are illustrated in Fig. 2A for patients with proximal DVT, isolated distal DVT and the total sample. As the diagnostic performance of D-dimer was worse at younger ages, the sample was stratified accordingly by the median age of the study sample, i.e. 60 years for further analysis. The distribution of clinical characteristics for both age groups is outlined in Supplemental Table 2. Comparison of the diagnostic performance of D-dimer between both age groups indicated marked differences regarding sensitivity and specificity for both the total sample and pre-specified subgroups (Table 2): In general, the sensitivity of D-dimer was always lower for the younger individuals. Intra-group analysis of patients < 60 years revealed the largest differences in sensitivity with regard to sex (female vs. male sex: −13.0%), aetiology of DVT (unprovoked vs. provoked: −13.1%), number of venous segments with thrombotic material (one segment vs. at least two segments: −36.3%), and site of DVT (isolated distal DVT vs proximal DVT: −20.7%).
Subgroup analyses of D-dimer testing. Proximal DVT versus distal DVT. For proximal DVT, sex-specific differences in the utility of D-dimer were assessed: for patients < 60 years of age, levels of sensitivity were 10.3% lower in females as compared to males. This finding was complemented by lower levels of sensitivity in unprovoked DVT (−15.2%) and in patients with a single thrombosed venous segment (−34.9%). For all sub-categories of patients ≥ 60 years, higher levels of sensitivity were observed (92.3% to 100%), which were accompanied by lower specificity (10.6% to 17.5%; see Supplemental Table 3). For isolated distal DVT, the absolute differences of sensitivity and specificity between both age groups were considerably higher as compared to proximal DVT. The differences in sensitivity between both age groups were most pronounced for female sex (−32.0%) and unprovoked DVT (−24.7%). Specificity was approximately 30% lower in patients ≥ 60 years of age in comparison to those < 60 years (see Supplemental Table 4).

Low-to-moderate pretest probability. In individuals with low-to-moderate pretest probability, a marked difference in test characteristics between age groups was detected: in patients < 60 years of age, sensitivity was lower at low-to-moderate pretest probability (73.2%, 95% confidence interval (CI) 61.4%/83.1%) as compared to patients with a high pretest probability (85.7%, 95%CI 63.7%/97.0%). For proximal DVT, sensitivity of D-dimer in individuals under 60 years at low-to-moderate pretest probability was 87.5% (95%CI 71.0%/96.5%). In contrast, sensitivity of D-dimer at low-to-moderate pretest probability was higher in patients ≥ 60 years for the total sample of DVT (94.4%, 95%CI 85.3%/97.0%) and the corresponding subsample of proximal DVT (100%, 95%CI 85.5%/100%), respectively.

Outpatients. Restriction of the study sample to outpatients confirmed age-related differences for D-dimer testing: in line with the results for the total sample, sensitivity of D-dimer was 18.2% lower in outpatients < 60 years of age as compared to outpatients ≥ 60 years (74.4%, 95%CI 63.6%/83.4%, vs. 92.6%, 95%CI 85.3%/97.0%). Similarly, lower levels of sensitivity were observed for proximal and distal DVTs in outpatients < 60 years compared to the elderly (Δsensitivity −9.8% and −27.8%, see Supplemental Table 5).

Optimized thresholds for D-dimer testing. An age-dependent threshold for D-dimer (age/100 mg/L FEU), which had recently been evaluated for elderly patients with suspected pulmonary embolism, was analysed in patients with suspected DVT ≥ 60 years of age: for proximal DVT, this cut-off value increased the specificity of D-dimer at steady levels of sensitivity. For isolated distal DVT, the increase in specificity was accompanied by lower levels of sensitivity compared to the established threshold of 0.5 mg/L FEU (Fig. 2B).

Due to the low level of sensitivity for D-dimer testing in younger individuals < 60 years, alternative age-specific cut-off values were evaluated for the biomarker: the age-dependent threshold (age/100 mg/L FEU) was compared to optimized fixed cut-off values, which may result in a higher feasibility in clinical routine, for both age groups. For proximal DVT, a fixed threshold of D-dimer displaying a sensitivity of 95% was detected at 0.25 mg/L FEU. In comparison to the common cut-off (0.5 mg/L FEU) and an age-dependent threshold (age/100 mg/L FEU), the fixed lower cut-off displayed higher sensitivity for patients < 60 years of age in the total sample and the sub-samples of proximal and isolated distal DVT, which was accompanied by lower specificity, however (Fig. 2B). The use of the optimized D-dimer threshold results in a reduction of DVT patients with negative D-dimer tests by 40.0% (2 out of 5 patients) in proximal DVT and by 50.0% in isolated distal DVT (12 out of 24 patients; see Figure 1. Flow diagram for a threshold of D-dimer at 0.5 mg/L FEU. Reasons for inconclusive test results were absence quality controlled data on concentration of D-Dimer in N = 56 individuals due to quantitative D-dimer testing, qualitative D-dimer test by non-certified external laboratories, or absence of adequate biomaterial. DVT, deep vein thrombosis.

Figure 1. Flow diagram for a threshold of D-dimer at 0.5 mg/L FEU. Reasons for inconclusive test results were absence quality controlled data on concentration of D-Dimer in N = 56 individuals due to quantitative D-dimer testing, qualitative D-dimer test by non-certified external laboratories, or absence of adequate biomaterial. DVT, deep vein thrombosis.
Supplemental Fig. 2). In patients at low-to-moderate pre-test probability, the D-dimer threshold of 0.25 mg/L FEU raised sensitivity of D-dimer testing in patients < 60 years from 73.2% (95%CI 61.4%/83.1%) to 91.5% (95%CI 82.5%/96.8%) at the cost of lower specificity (16.1%, 95%CI 10.1%/23.8%). Consistent observations were made in the subsample of outpatients < 60 years of age at low-to-moderate pretest probability (sensitivity: 90.9%, 95%CI 81.3%/96.6%, specificity: 15.7%, 95%CI 9.5%/23.6%; see Supplemental Table 6) resulting in an overall NPV of 92.3% (95%CI 86.7%/96.1%).

**Figure 2.** Age-dependent diagnostic performance of D-dimer in patients with suspected DVT according to different diagnostic thresholds. Pattern A (left side) illustrates the diagnostic performance of the established D-dimer threshold of 0.5 mg/L FEU. Sensitivity (red line) and specificity (blue line) of D-dimer are displayed according to age for patients with proximal DVT, patients with isolated distal DVT, and in the total sample. Pattern B (right side) depicts the diagnostic performance of optimized D-dimer thresholds for sensitivity (red line) and specificity (blue line) in proximal DVT, isolated distal DVT, and the total sample. Solid lines illustrate age-specific fixed thresholds (for patients < 60 years: 0.25 mg/L FEU D-dimer and for patients ≥ 60 years: 0.5 mg/L FEU D-dimer), whereas dashed lines show an age-dependent threshold (age/100 mg/L FEU D-dimer). DVT, deep vein thrombosis.

**Value of C-reactive protein in patients with suspected DVT.** Against the background of the limitations of D-dimer testing in young patients with suspected DVT that were identified in the analysis and the role of inflammation in venous thrombosis8,10, we evaluated CRP – a commonly available inflammatory biomarker in clinical routine – as alternative biomarker in the diagnostic setting of patients with suspected DVT (see Supplemental Tables 3, 4 and 7). After incorporation of information on sex and the Wells score, receiver operating characteristic (ROC) curves demonstrated comparable diagnostic performance of CRP and D-dimer in patients < 60 years of age for proximal DVT (AUC_{D-dimer} : 0.842 vs. AUC_{CRP} : 0.831) and isolated distal DVT (AUC_{D-dimer} : 0.674 vs. AUC_{CRP} : 0.667) (for both, P for difference > 0.05; Fig. 3). In patients ≥ 60 years, D-dimer showed a higher AUC in comparison to CRP for proximal DVT (AUC_{D-dimer} : 0.865 vs. AUC_{CRP} : 0.679; P for difference < .001), whereas no statistically-significant difference was detected for isolated distal DVT (AUC_{D-dimer} : 0.622 vs. AUC_{CRP} : 0.604; P for difference = 0.33).

In order to evaluate both biomarkers at best performance with regard to sensitivity, we subsequently investigated the diagnostic utility of an optimized diagnostic threshold of CRP for patients < 60. Similarly to D-dimer, a cut-off value of CRP providing 95% sensitivity for proximal DVT was identified at 1.0 mg/L. Comparison of the diagnostic performance for the optimized fixed thresholds of both biomarkers in patients < 60 years did not result in relevant differences of the diagnostic utility of CRP for proximal DVT (c-index_{D-dimer} : 0.562 vs. c-index_{CRP} : 0.543) or isolated distal DVT (c-index_{D-dimer} : 0.518 vs. c-index_{CRP} : 0.487) in comparison to D-dimer (Table 3; for both: P for difference > 0.05).
Table 2. Diagnostic performance of D-dimer in patients with suspected DVT (N = 444) according to age groups. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) are provided as relative frequency with according 95% confidence interval for a D-dimer threshold of 0.5 mg/L FEU. Absolute frequency (no.) of DVT cases is denoted for all subgroups. Reference group for the stratified analysis of DVT cases by aetiology, sex, and site, and number of venous segments with thrombotic material was patients without DVT. Classification of pre-test probability: low-to-moderate: Wells score 0–2; high: Wells score ≥3. DVT, deep vein thrombosis.

Discussion

The present work investigated the age-dependent performance of D-dimer testing in an all-comer study of individuals with suspected DVT and revealed clinically-relevant limitations: The diagnostic ability of D-dimer was substantially lower in individuals aged less than 60 years, especially in individuals of female sex and with unprovoked aetiology. The use of a lower fixed threshold for D-dimer (0.25 mg/L FEU) in patients <60 years resulted in an improvement of sensitivity for both proximal DVT and isolated distal DVT at lower specificity. Of clinical importance, the discriminative ability of D-dimer and CRP did not differ for individuals <60 years.

D-dimer assays as sensitive and non-specific markers for DVT have been studied extensively in patients with suspected DVT. Sensitivity (85–98%) and specificity (26–58%) of D-dimer assays for proximal DVT vary between latex agglutination assays and whole blood assays in literature. In the current study, D-dimer showed comparable levels of sensitivity (94.5%, 95%CI 87.6 to 98.2%) and specificity (26.6%, 95%CI 22.9 to 34.8%) for proximal DVT. The well-known increase of circulating D-dimer in patients with increasing age led to efforts evaluating the use of age-dependent thresholds of D-dimer in older patients with suspected DVT. In line with a previous study investigating patients >50 years with suspected pulmonary embolism, we confirmed an increase of specificity at steady levels of sensitivity for an age-dependent D-dimer cut-off value in patients >60 years with suspected DVT. However, the age-specific analysis identified decreased levels of sensitivity of D-dimer in patients <60 years as compared to >60 years, especially in individuals with unprovoked events and with female sex, which have not been reported in literature yet. This finding was also confirmed when restricting the study sample to outpatients. Since ageing is a well-known “risk factor” to promote inflammatory processes, to alter immune response and to change the balance of primary and secondary haemostasis, both the development and process of thrombus resolution may differ between DVT patients by age. In a mouse model of stasis induced thrombosis, aging was demonstrated to be associated with impaired thrombus resolution. Interestingly, investigations in paediatric samples lead to the concept of developmental haemostasis indicating that the levels of markers reflecting the coagulation system already differ at early stage in life. Recently, two studies indicated a need for age-specific reference values of D-dimer due to substantially lower concentrations of D-dimer in younger healthy individuals as compared to the elderly. In the present study, the use of a fixed threshold of 0.25 mg/L FEU for D-dimer in patients <60 years resulted in an improvement of sensitivity for both proximal and isolated distal DVT. This improvement of sensitivity was especially observed in the clinically-relevant group of patients with suspected DVT at low-to-moderate pre-test probability. As expected, the approach to decrease the amount of false negatives (i.e. missed cases of DVT) was accompanied by lower specificity as cut-off values represent always a trade-off between sensitivity and specificity. Therefore, age-range specific cut-off values of D-dimer merit consideration for the clinical diagnostic setting of DVT.
It is known from literature that D-dimer has lower sensitivity in isolated distal than in proximal DVT. The lower sensitivity in patients with isolated distal DVT in the present study compared to a recent report is explained by the higher frequency of young individuals, which implies lower levels of sensitivity. The low sensitivity of D-dimer in isolated distal DVT substantiates the dependence of the diagnostic accuracy of this marker on the extent of thrombotic burden or lower fibrinolytic activity, coherently to the correlation of its diagnostic accuracy with the number of segments with thrombotic material in patients with proximal DVT. The different diagnostic ability of D-dimer testing in patients with proximal and isolated distal DVT merits careful attention since D-dimer testing, which is routinely available in outpatient settings via quantitative and qualitative D-dimer assays, is commonly applied to patients with suspected DVT < 60 years irrespective of the DVT phenotype. The present study showed a sensitivity of 87.0% for isolated distal DVT at an optimized D-dimer threshold of 0.25 mg/L FEU for patients < 60 years, although it is still to be critically evaluated whether a specificity of < 20% is acceptable for routine application in daily practice.

The finding that CRP was non-inferior to D-dimer for diagnostics in all subgroups of younger patients with suspected DVT sheds new light on the role of inflammatory processes in the pathophysiology of DVT. CRP reflects systemic inflammation as acute-phase protein and is often routinely measured in patients with elevated levels of D-dimer in the absence of clinical symptoms of DVT. Although preclinical studies have established that DVT and inflammatory processes are interacting, scientific evidence has been conflicting regarding the diagnostic utility of CRP as biomarker in patients with suspected DVT. The present study indicates that CRP can be...
The variability in the inflammatory and immune response dependent on age – “inflammaging” and “immunosenescence” – explains the differences observed in the diagnostic performance of D-dimer and the presence of DVT. The concept of immunothrombosis should be considered, which refers to the evolutionary conserved link between coagulation and innate immunity, and focuses on the prothrombotic ability of innate immune cells. Last, since elevated levels of CRP are frequently observed in health states, which coincide with increasing age (e.g., diabetes, cardiovascular disease, cancer or rheumatic disorders), it seems consistent that CRP shows a better diagnostic performance in younger individuals, who are more likely to have lower levels in a DVT-free status, as compared to the elderly.

### Limitations
There are several limitations of the present study, which merit consideration. The lower levels of sensitivity in individuals with female sex and unprovoked DVT underline the need for optimization of diagnostic approaches and risk assessment strategies. However, the sample size – despite the fairly large size compared to literature – restricted the assessment of sex-specific cut-off values and subgroup analyses. Moreover, two assays for D-dimer testing have been applied in the present study, which might have introduced a bias that contributes to the explanation of the findings. Yet, it seems unlikely, since the assays show a high correlation (r = 0.973, see Supplemental Table 1 and Supplemental Fig. 1). Finally, when interpreting this study, it needs to be considered that the performance of clinical decision rules such as the Wells score, and the prevalence of DVT cases as well as the age of patients in the study sample.

### Conclusion
This study demonstrates a substantially lower sensitivity of D-dimer in individuals with suspected DVT aged less than 60 years. In this age group, especially individuals with female sex, unprovoked DVT and low thrombotic burden of DVT were identified as risk groups for worse diagnostic abilities of the marker. An optimized age-specific D-dimer threshold was defined with 0.25 mg/L FEU for these patients resulting in a substantial improvement of sensitivity, especially in patients at low-to-moderate pre-test probability. Of clinical importance, the diagnostic performance of CRP in suspected DVT was comparable to that of D-dimer in all subgroups of patients.

### Methods
#### Study design
The background, rationale and study design of the VTEval project have been published recently. The study is carried out by the Center for Thrombosis and Hemostasis in Mid-Western Germany, recruiting patients with a clinical suspicion of acute DVT aged ≥ 18 years. All study participants provided informed written consent for the study participation. The study conduct is performed according to the principles.
of good clinical practice and the principles outlined in the Declaration of Helsinki; approval by the local ethics committee (medical association of the federal state Rhineland-Palatinate, Germany; reference no. 837.320.12 (8421–F)) and the data safety commissioner of the University Medical Center of the Johannes Gutenberg University Mainz was obtained. The VT Eval project was registered online at clinicaltrials.gov (identifier: NCT02156401).

Assessment of clinical phenotype. The sample for the present report represents a consecutive sample of patients with suspected DVT, who were examined in the Department of Angiology at the University Medical Center Mainz between April 2013 and July 2015. Within the investigation, a standardized clinical examination, a computer-assisted personal interview and venous blood sampling were performed according to standard operating procedures. Blood samples were collected from all participants before conduct of CDUS. All patients with suspected DVT underwent a standardized clinical examination considering signs and symptoms of acute DVT. Subsequently, Wells score was calculated and the cohort was divided according to pre-test probability into subgroups. All study participants underwent CDUS after assessment of Wells score and measurement D-dimer concentration. All information was entered in electronic case report forms with pre-defined validity checks and cross-checked with clinical records. All study information including clinical and laboratory data underwent data management with detailed quality control and checks for plausibility.

Measurement of biomarkers and diagnosis of DVT. Concentrations of D-dimer and CRP were collected in citrated venous blood samples. D-dimer was quantified by quantitative turbidimetric immunoassays: Innovance D-dimer BCS (Siemens Healthcare Diagnostics Products, Germany) from 04/2013 to 07/2014 and HemosIL D-dimer HS 500 for ACL TOP 700 (Instrumentation Laboratory, USA) from 08/2014 to the end of study. C-reactive protein was measured by a latex particle-enhanced turbidimetric immunoassay (Abbott Laboratories, USA). Biomarkers were categorized as within or above normal range according to the clinically established cut-off values of 0.5 mg/L fibrinogen equivalent unit (FEU) for D-dimer and 5.0 mg/L for CRP. Participants were diagnosed as DVT cases by trained angiologists, who were blinded from the Wells score and D-dimer results, based upon the results of CDUS. Clinical decision on diagnosis or exclusion of DVT was validated by an experienced, board-certified senior angiologist. Proximal DVT was defined as venous thrombosis in the popliteal, femoral, or iliac vein of the lower limb, whereas isolated distal DVT was defined as being located below the knee with confinement to the calf veins (peroneal, posterior, anterior tibial, and muscular veins). In the case of DVT, patients received oral anticoagulation therapy according to current guidelines. Based on the medical report and the information obtained during the investigation, cases were subsequently categorized in subgroups (unprovoked vs. provoked DVT, proximal versus isolated distal DVT).

Statistical analysis. Dichotomous variables are presented as absolute and relative frequencies. Continuous variables are reported as mean with standard deviation (SD) for normally distributed values or as median with interquartile range (IQR) where appropriate. Test characteristics (sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV)) were calculated. Receiver operating characteristic curves were built using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica 62, 258–262 (1995).

References
1. White, R. H. The epidemiology of venous thromboembolism. Circulation 107, 14–8, doi:10.1161/01.cir.0000078488.11849.66 (2003).
2. Bates, S. M. et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e3515–4185, doi:10.1378/chest.11-2299 (2012).
3. Adam, S. S., Key, N. S. & Greenberg, C. S. D-dimer antigen: current concepts and future prospects. Blood 113, 2878–2887, doi:10.1182/blood-2008-06-165845 (2009).
4. Lippi, G., Bonfanti, L., Saccenti, C. & Cervellin, G. Causes of elevated D-dimer in patients admitted to a large urban emergency department. European journal of internal medicine 25, 45–48, doi:10.1016/j.ejim.2013.07.012 (2014).
5. Righini, M., Goehring, C., Bounnameaux, H. & Perrier, A. Effects of age on the performance of common diagnostic tests for pulmonary embolism. The American journal of medicine 109, 357–361 (2000).
6. Konstantinides, S. V. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. European heart journal 35, 3033–3069, 3069a–3069h, doi:10.1093/eurheartj/ehu283 (2014).
7. Schouten, H. J. et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ 346, f2492, doi:10.1136/bmj.f2492 (2013).
8. Righini, M. et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST–PE study. JAMA 311, 1117–1124, doi:10.1001/jama.2014.2135 (2014).
9. von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. The journal of experimental medicine 209, 819–835, doi:10.1084/jem.20112322 (2012).
10. Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nature reviews. Immunology 13, 34–45, doi:10.1038/nri3345 (2013).
11. Goodacre, S., Sampson, F. C., Sutton, A. J., Mason, S. & Morris, E. Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM 98, 513–527, doi:10.1093/qjmd/hcc088 (2005).
12. Heim, S. W., Schectman, J. M., Siadaty, M. S. & Phiblick, J. T. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical chemistry 50, 1136–1147, doi:10.1373/clinchem.2004.031765 (2004).
13. Kovacs, M. J. et al. A comparison of three rapid D-dimer methods for the diagnosis of venous thromboembolism. British journal of haematology 115, 140–144 (2001).
14. Flores, J. et al. Efficacy of D-dimer and total fibrin degradation products evaluation in suspected pulmonary embolism. Respiration 62, 258–262 (1995).
15. Dousa, R. A. et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica 97, 1507–1513, doi:10.3324/haematol.2011.060657 (2012).
16. Schouten, H. J. et al. Validation of two age dependent D-mimer cut-off values for exclusion of deep vein thrombosis in suspected elderly patients in primary care retrospective, cross sectional, diagnostic analysis. BMJ 344, e2985, doi:10.1136/bmj.e2985 (2012).

17. Sepulveda, C., Palomo, I. & Fuentes, E. Primary and secondary haemostasis changes related to aging. Mechanisms of ageing and development 150, 46–54, doi:10.1016/j.mad.2015.08.006 (2015).

18. Paczek, L., Michalska, W. & Burtlomieczyk, I. Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age and ageing 37, 318–323, doi:10.1093/ageing/afu039 (2008).

19. Das, R. et al. Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation 127, 1209–1218, e1201–1216, 10.1161/circulationaha.112.001214 (2013).

20. McDonald, A. P. et al. Aging is associated with impaired thrombus resolution in a mouse model of stasis induced thrombosis. Thrombosis research 125, 72–78, doi:10.1016/j.thromres.2009.06.005 (2010).

21. Toulon, P. et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thrombosis and haemostasis 116, 9–16, doi:10.1160/h15-12-0964 (2016).

22. Großmann, V. et al. Sensitive D-Mimer Testing Predicts Cardiovascular Risk, Clinical Research in Cardiology 104, 100039, doi:10.1007/s00392-015-1100-4 (2015).

23. Haase, C., Joergensen, M., Ellervik, C., Joergensen, M. K. & Bathum, L. Age- and sex-dependent reference intervals for D-dimer: evidence for a marked increase by age. Thrombosis research 132, 676–680, doi:10.1016/j.thromres.2013.09.033 (2013).

24. Vasan, R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 2335–2362, doi:10.1161/circulationaha.104.482570 (2006).

25. Sartori, M. et al. The Wells rule and D-mimer for the diagnosis of isolated distal deep vein thrombosis. Journal of thrombosis and haemostasis 10, 2264–2269, doi:10.1111/j.1538-7836.2012.04895.x (2012).

26. Geersing, G. J. et al. Diagnostic accuracy and user-friendliness of 3 point-of-care D-mimer tests for the exclusion of deep vein thrombosis. Clinical chemistry 56, 1758–1766, doi:10.1373/clinchem.2010.147892 (2010).

27. Bucke, R. A., Reiter, M., Quenenberger, P. & Minar, E. C-reactive protein in the diagnosis of deep vein thrombosis. British journal of haematology 119, 385–389 (2002).

28. Syrjäla, H., Haukipuro, K. & Kiviniemi, H. Acute phase response and deep lower limb venous thrombosis. Journal of clinical pathology 43, 519–520 (1990).

29. Thomas, E. A., Cobby, M. J., Rhys Davies, E., Jeans, W. D. & Whicher, I. T. Liquid crystal thermography and C reactive protein in the detection of deep venous thrombosis. BMJ 299, 951–952 (1989).

30. Pawelec, G. T-cell immunity in the aging human. Haematologica 99, 795–797, doi:10.3324/haematol.2013.094383 (2014).

31. Paewecl, G., Goldeck, D. & Derholovassian, E. Inflammation, aging and chronic disease. Current opinion in immunology 29, 23–28, doi:10.1016/j.coi.2014.03.007 (2014).

32. Siemes, C. et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. Journal of clinical oncology 24, 5216–5222, doi:10.1200/jco.2006.07.1381 (2006).

33. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327–334 (2001).

34. Bailey, A. L., Scantlebury, D. C. & Smyth, S. S. Thrombosis and antithrombotic therapy in women. JAMA internal medicine 175, 1112–1117, doi:10.1001/jamainternmed.2015.1687 (2015).

35. Eichinger, S., Heinze, G., Jandeck, L. M. & Kyrle, P. A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121, 1630–1636, doi:10.1161/circulationaha.109.925214 (2010).

36. Irwig, L., Bossuyt, P., Glasziou, P., Gatsonis, C. & Lijmer, J. Designing studies to ensure that estimates of test accuracy are transferable. BMJ 324, 669–671 (2002).

37. Silveira, P. C. et al. Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. JAMA internal medicine 175, 1112–1117, doi:10.1001/jamainternmed.2015.1687 (2015).

38. Frank, B. et al. Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTiV Project. BMJ open 5, e008157, doi:10.1136/bmjopen-2015-008157 (2015).

39. Bossuyt, P. M. et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351, h5527, doi:10.1136/bmj.h5527 (2015).

40. R. A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2014).

Acknowledgements
We are indebted to all study participants of the VTiV project and all co-workers of the Department of Angiology, the Emergency Department, and the Center for Thrombosis and Hemostasis of the University Medical Center of the Johannes Gutenberg University Mainz.

Author Contributions
P.S.W. and J.H.P. had full access of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have read and approved the manuscript in its current form. Study concept and design: P.S.W., S.K. Acquisition, analysis, or interpretation of data: J.H.P., B.F., M.N., H.L., G.W., A.S., L.E., S.G., N.A., M.P., I.H., A.P., S.K., H.t.C., K.J.L., T.M., C.E.K., P.S.W. Data management: H.L., J.H.P., M.N., L.E. Statistical analysis: J.H.P., M.N., A.S., P.S.W. Drafting of manuscript: J.H.P., B.F., P.S.W. Critical revision of manuscript for important intellectual content: J.H.P., B.F., M.N., H.L., G.W., A.S., L.E., S.G., N.A., M.E.N., I.H., A.P., S.K., H.t.C., K.J.L., T.M., C.E.K., P.S.W. Study supervision: P.S.W.

Additional Information
Supplementary Information accompanies this paper at this web address: 10.1038/s41598-017-04843-x

Competing Interests: This work was supported by the German Federal Ministry of Education and Research (BMBF 01EO1003) and the Center for Translational Vascular Biology (CTVB) of the University Medical Center Mainz (P.S.W.). H.t.C. is Fellow of the Gutenberg Research Foundation. The funders played no role with regard to design and conduct of the study, data collection, study management, analysis and interpretation of the data, preparation, review or approval of the manuscript, and decision for publication. The other authors declare no competing financial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
